Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8694MR)

This product GTTS-WQ8694MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8694MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4255MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ10449MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ6365MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ15853MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ3713MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ10651MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ6166MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW